Latham Advises on Pacira BioSciences, Inc. in Pricing of US$250 Million in Convertible Senior Notes

Pacira BioSciences, Inc. (Nasdaq: PCRX) has announced the pricing of US$250 million aggregate principal amount of convertible senior notes due 2029 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional US$37.5 million aggregate principal amount of notes. Pacira intends to use the proceeds from the offering to repurchase existing outstanding convertible notes and shares of its common stock, and for general corporate purposes, including working capital, and research and development expenditures.

Latham & Watkins LLP advised the initial purchasers of notes with a capital markets team led by Los Angeles/New York partner Greg Rodgers and New York Partner Nathan Ajiashvili, with associates Ryan Gold, Roger Yarett, Andrew Bentz, and Richard Dacher. Advice was provided on derivatives matters by New York partner Eric Rice, with associates Shawn Noh and Henry Lin; and on tax matters by New York partner Elena Romanova, with associate James Aldred.